期刊文献+

蛋白激酶Cε过量表达与乳腺癌临床病理特征的关系 被引量:6

Association of overexpression of PKCε with clinicopathological features of breast cancer
下载PDF
导出
摘要 目的探讨蛋白激酶Cε(protein kinase C epsilon,PKCε)在乳腺组织中的表达及其过量表达与浸润性乳腺癌临床病理特征的关系。方法采用免疫组化法检测正常乳腺组织(33例)、导管原位癌(26例)及浸润性乳腺癌(126例)中PKCε的表达情况,分析其表达水平与乳腺癌临床病理特征的关系。结果PKCε在乳腺浸润性癌中的表达高于其在正常乳腺(P<0.05)和导管原位癌组织(P<0.05)中的表达,且与乳腺癌的组织学类型相关(P<0.05)。PKCε的过量表达与乳腺癌是否发生淋巴结转移、组织学分级、PR和HER2的表达相关(P<0.05),与患者年龄、癌灶大小、TNM分期、Ki67指数及ER的表达无显著相关(P>0.05)。结论PKCε的过量表达与乳腺癌的发生、转移及不良预后密切相关,检测PKCε的表达水平可作为乳腺癌预后判断的独立指标。 Objective To investigate the association of the expression and overexpression of protein kinase C epsilon(PKCε)in breast tissue with clinicopathological features of invasive breast cancer.Methods Immunohistochemistry was used to detect the expression of PKCεin normal breast tissue(n=33),ductal carcinoma in situ(n=26)and invasive breast cancer(n=126).and the clinicopathological characteristics of breast cancer were analyzed.Results The expression of PKCεin invasive breast cancer was higher than that in normal breast tissue(P<0.05)and ductal carcinoma in situ(P<0.05),and the expression level was correlated with the histological type of breast cancer(P<0.05).Over expression of PKCεwas correlated with lymph node metastasis,histological grade,PR and HER2 expression(P<0.05),but not significantly with age,tumor size,TNM stage,Ki67 index and ER expression(P<0.05).Conclusion The overexpression of PKCεwas closely related to the occurrence,metastasis and poor prognosis of breast cancer.Detection of the expression of PKCεcould be used as an independent prognostic indicator of breast cancer.
作者 方晓露 徐冬娟 胥明远 张红梅 蒋宗英 吕怀盛 FANG Xiaolu;XU Dongjuan;XU Mingyuan;ZHANG Hongmei;JIANG Zongying;LÜHuaisheng(Department of pathology and pathophysiology,Ningxia Medical University,Yinchuang 750004,China;不详)
出处 《实用医学杂志》 CAS 北大核心 2020年第1期11-15,共5页 The Journal of Practical Medicine
基金 国家自然科学基金项目(编号:81360308) 宁夏自然科学基金资助项目(编号:NZ17179)
关键词 乳腺癌 蛋白激酶CΕ 临床病理特征 免疫组织化学 breast cancer PKCε clinicopathological feature immunohistochemical staining
  • 相关文献

参考文献4

二级参考文献47

  • 1Viale G,Regan MM,Maiorano E,et al.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98[J].J Clin Oncol,2007,25(25):3846-3852.
  • 2Rhodes A,Jasani B,Balaton AJ,et al.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas:Correlation with patient age,assay sensitivity,threshold value,and mammographic screening[J].J Clin Pathol,2000,53(9):688-696.
  • 3Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
  • 4Harvey JM,Clark GM,Osbome CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 5Elledge RM,Green S,Pugh R,et al.Estrogen receptor(ER)and progesterone receptor(PgR),by ligand-binding assay compared with ER,PgR and pS2,by immunohistocheniistiy in predicting response to tamoxifen in metastatic breast cancer:A Southwest Oncology Group study[J].Int J Cancer,2000,89?2):111-117.
  • 6Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 7Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 8Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9);2206-2223.
  • 9Taylor CR,Levenson RM.Quantification of immunohistochemistry:Issues concerning methods,utility and semiquantitative assessment II[J].Histopathology,2006,49(4):411-424.
  • 10Yaziji H,Taylor CR,Goldstein NS,et al.Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry[J].Appl Immunohistochem Mol Morphol,2008,16(6):513-520.

共引文献334

同被引文献70

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部